- Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
- 2 A.M. Turner¹, L. Li¹, I.R. Monk¹, J.Y.H. Lee^{1,2}, D.J. Ingle¹, S. Duchene¹, N.L. Sherry^{1,3,4}, T.P.
- 3 Stinear¹, J.C. Kwong^{1,4}, C.L. Gorrie^{1,3}*, B.P. Howden^{1,3,4}*† and G.P. Carter¹*†
- 5 ¹Department of Microbiology & Immunology, The Peter Doherty Institute for Infection and
- 6 Immunity, The University of Melbourne, Melbourne, VIC, Australia
- 7 ²Department of Infectious Diseases, Monash Health, Clayton, VIC, Australia
- 8 ³Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and
- 9 Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and
- 10 Immunity, Melbourne, VIC, Australia
- 11 ⁴Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia
- *These authors supervised this work equally.
- †Corresponding authors: glen.carter@unimelb.edu.au, bhowden@unimelb.edu.au
- 15 **Abstract**

1

4

- 16 Bacterial pathogens such as vancomycin-resistant Enterococcus faecium (VREfm) that are
- 17 resistant to almost all antibiotics are among the top global threats to human health.
- 18 Daptomycin is a new last-resort antibiotic for VREfm infections with a novel mode-of-action,
- 19 but for which resistance has surprisingly and alarmingly been widely reported. The causes of
- such a rapid emergence of resistance to this novel antibiotic have been unclear. Here we show
- 21 that the use of rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic
- 22 encephalopathy in liver disease patients, is causing resistance to this last-resort antibiotic in
- 23 VREfm. We show that mutations within the bacterial RNA polymerase complex confer cross-
- 24 mestis tempo ebon bedans inferviers and los perceny continuative may be a serial cutada consumerative

spread globally across at least 5 continents and 20 countries, making this a major yet previously unrecognised mechanism of resistance. Until now, rifaximin has been considered 'low-risk' for development of antibiotic resistance. Our study shows this is not the case and that widespread rifaximin use may be compromising the clinical efficacy of daptomycin, one of the major last-resort interventions for multidrug resistant pathogens. These findings demonstrate that unanticipated antibiotic cross-resistance may potentially undermine global strategies designed to preserve the clinical use of last-resort antibiotics.

Main

Antimicrobial resistance (AMR) is one of the greatest public health threats that humanity currently faces, with 1.27 million deaths being directly attributable to bacterial AMR in 2019¹. The magnitude of this threat is therefore similar to that of malaria (558,000 global deaths in 2019)², HIV (690,000 deaths in 2019)³, and diabetes mellitus (1.5 million deaths in 2019)⁴. Infectious caused by multidrug (MDR) and extensively drug resistant (XDR) pathogens are of particular clinical concern since they are associated with frequent treatment failure and high-rates of morbidity and mortality. The preservation of last-resort antibiotics that can be used to treat these formidable pathogens is of critical importance.

Enterococcus faecium is one such formidable pathogen. It is a commensal of the human gastrointestinal tract that has emerged as a major nosocomial pathogen⁵. The intrinsic antibiotic resistance of hospital-associated clones coupled with their ability to rapidly acquire additional antibiotic resistance genes makes *E. faecium* infections increasingly difficult to treat⁶. In particular, strains resistant to vancomycin, the first-line antibiotic for invasive infections, have emerged and disseminated globally due to the acquisition of transferable *van*

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

resistance genes⁷. Consequently, E. faecium, which is one of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), has been recognised by the World Health Organization (WHO) as a 'high priority' bacterial pathogen⁸. The lipopeptide daptomycin is a WHO designated 'last-resort' antibiotic that is used 'off-label' to treat severe vancomycin-resistant *E. faecium* (VREfm) infections⁹. The increasing reports of daptomycin-resistant VREfm are of great clinical concern. The specific risk factors for acquiring a daptomycin-resistant VREfm strain are poorly understood, however, patients with a daptomycin-resistant, bloodstream isolate are generally more likely to have been exposed to daptomycin^{10,11}. Daptomycin resistance in clinical strains is commonly associated with the presence of specific mutations in the regulatory system LiaRS and cardiolipin synthase Cls¹²⁻ ¹⁴. However, many daptomycin-resistant VREfm contain wild-type (WT) liaRS and cls alleles, indicating other unknown molecular pathways are involved 13,15,16. In Australia, high rates (15%) of daptomycin-resistant VREfm were recently reported 17, but the data were not epidemiologically robust and genetic determinants leading to resistance were not defined. Accordingly, we undertook a combined genomic and phenotypic analysis to investigate the daptomycin resistance mechanisms in VREfm. Here we show that daptomycin resistance can emerge de novo in VREfm following exposure to rifaximin, a commonly prescribed antibiotic used prophylactically to prevent hepatic encephalopathy¹⁸ in liver disease patients. Further, we show that rifaximin-mediated daptomycin resistance is linked with the presence of novel mutations (G482D, H486Y, and S491F) within the rifampicinresistance determining region (RRDR) of RpoB. Importantly, patients given rifaximin were significantly more likely to harbour daptomycin-resistant VREfm (that also carried RpoB mutations) than patients who did not receive rifaximin. Finally, we show that the identified RpoB mutations arose within the VREfm population soon after rifaximin was first approved for clinical use and have since become globally established, with three independent VREfm lineages currently circulating within at least 20 countries. Our work has therefore uncovered a major new mechanism of daptomycin resistance in VREfm and identified rifaximin, an antibiotic considered to be low-risk for the emergence of bacterial resistance¹⁹, as an important driver of last-resort antibiotic resistance.

Results

Daptomycin resistance in Australian VREfm is polygenic and does not correlate with known

resistance determinants.

Daptomycin susceptibility testing was performed on VREfm isolated during two unbiased state-wide 'snapshot' studies undertaken for month-long periods in 2015 (n=294) and 2018 (n=423) in Victoria, Australia. The proportion of isolates resistant to daptomycin was 16.6% (n=49) in 2015 and 15.3% (n=65) in 2018. Given the unexpectedly high rate of resistance observed, we expanded the study to include additional VREfm isolated in 2017 (n=108) and 2018 (n=173) as part of the 'Controlling Superbugs' flagship study^{20,21}, with 28.4% (n=80) of these isolates being resistant to daptomycin. Overall, we observed 189 (18.9%) daptomycin-resistant VREfm isolates, indicating a very high prevalence of daptomycin resistance in Victoria, Australia.

To investigate the relationship between daptomycin-resistant and daptomycin-susceptible VREfm, whole-genome comparisons were made for the 998 study isolates plus two additional

finished VREfm genomes (one daptomycin-susceptible and one daptomycin-resistant). A maximum-likelihood phylogeny was inferred from an alignment of 6,574 core genome single nucleotide polymorphisms (SNPs) (Supplementary Figure 1). *In silico* multi-locus sequence typing identified 36 sequence types (STs) within the 1000 isolates; 30 of these STs included at least one of the 189 daptomycin-resistant VREfm. Daptomycin resistance was interspersed throughout the tree (i.e. mostly polyphyletic), with several distinct clades. The largest clade (ST203) of daptomycin-resistant strains, accounted for 42.3% of resistant isolates (n=80 of 189) and consisted of a single clone predominant during our sampling timeframe (2015 to 2018), suggestive of an expanding daptomycin-resistant lineage. The other predominant STs (ST80, ST796, ST1421, and ST1424) consisted of several groups of resistant isolates that did not cluster based on tree structure. The presence of daptomycin-resistant isolates in distinct genetic backgrounds suggested daptomycin resistance has arisen independently within this VREfm population on multiple occasions.

Given the high prevalence of daptomycin resistance in Australian VREfm isolates, we sought to determine the genetic determinants leading to resistance. Only seven daptomycin-resistant isolates (3.7%) contained the dual LiaR W73C and LiaS T120A mutations. This finding is of note since current literature suggests these mutations are the most important mechanism of daptomycin resistance in VREfm^{9,12,22}. In addition, no daptomycin-resistant isolates contained the H215R or R218Q mutations in Cls or the Q75K mutation in the septum site determining protein (DivIVA), which have all previously been linked with daptomycin resistance in VREfm²³. The mechanism of daptomycin resistance in the majority (n=182) of our resistant study isolates was therefore left largely unexplained by previously characterised mutations.

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

S491F mutation.

The S491F mutation in RpoB is a novel mediator of daptomycin resistance in VREfm. To identify the mutations associated with daptomycin resistance in our study isolates, we performed a genome-wide association study (GWAS) approach on the collection of 1,000 VREfm isolates with known daptomycin MIC (Figure 1A). To account for the clonal population structure of the collection, we first removed non-homoplastic variants from the list of core genome mutations to reduce the data set to variants that were acquired at least twice across the phylogeny. We then applied a linear mixed model using a kinship matrix as a random effect. After correcting for multiple testing, the analysis identified 142 mutations (in 73 genes) significantly ($P < 1x10^{-10}$) associated with daptomycin resistance (as a binary variable with a breakpoint of 8 mg L⁻¹). The top five most significant mutations were (i) 1274S in an uncharacterised ABC efflux protein ($P = 7.44 \times 10^{-15}$), (ii) G71S in an uncharacterised permease protein ($P = 7.77 \times 10^{-14}$), (iii) V288L in a mannitol dehydrogenase protein ($P = 6.08 \times 10^{-12}$), (iv) S491F in RpoB, which is the RNA polymerase ß subunit (P=1.57x10⁻¹³), and (v) T634K in RpoC, which is the RNA polymerase β' subunit ($P=4.40 \times 10^{-11}$). Deletion of the genes encoding the ABC efflux protein, permease protein, or mannitol dehydrogenase protein had no impact on daptomycin susceptibility in a clinical daptomycinsusceptible strain of VREfm from the ST796 genetic background. Similarly, introduction of the T634K mutation within RpoC did not lead to increased levels of daptomycin resistance. However, introduction of the S491F substitution within RpoB, resulted in a 4-fold increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹, and a daptomycin-resistant phenotype. Since mutations within rpoB have previously been associated with daptomycin resistance in Staphylococcus aureus^{24,25}, we focused further experimental investigations on the RpoB

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

Based on amino acid alignment, the S491F mutation is located within the predicted RRDR of E. faecium RpoB, which spans amino acids 467 to 493 (inclusive). The majority of study isolates (n=829, 82.9%) contained a WT RRDR; however, 169 (16.9%) VREfm contained at least one mutation within this region (Figure 1B), with the S491F mutation being the most common (n=105). This was followed by H486Y (n=16), G482D (n=12), G482V (n=10), Q473L (n=6), H486R (n=5), and other uncommon (n=3) mutations. Different mutations within the RRDR of RpoB result in daptomycin resistance in VREfm. Given the association of the S491F mutation in RpoB with daptomycin resistance, we hypothesised that other mutations within RpoB may also alter daptomycin susceptibility (Figure 1B). In keeping with this hypothesis, we observed a putative correlation between strains carrying individual G482D (n=12) and H486Y (n=16) mutations in RpoB and daptomycin resistance, with 10 daptomycin-resistant isolates containing G482D (83.3% resistant) and 13 containing H486Y (81.3% resistant). Clinical isolates containing the G482D, H486Y, or S491F mutations were interspersed throughout the phylogenetic tree and identified in distinct STs, highly suggestive of multiple independent acquisitions (Figure 1C). Ongoing expansion was also observed for one dominant, daptomycin-resistant clone (ST203) containing the S491F mutation throughout the isolate collection period (2015-2018). The G482D and H486Y mutations were also located within the predicted RRDR region, suggesting a potential correlation between rifamycin and daptomycin resistance. Therefore, rifampicin susceptibility testing (with rifampicin being a marker of rifamycin resistance²⁶) was performed on all clinical VREfm containing a RpoB mutation within the predicted RRDR

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

(n=169). A randomly selected collection (n=169) of isolates containing a WT RpoB RRDR were used as a control group in this analysis. Mutations located within the predicted RRDR correlated with high-level rifampicin resistance (median MIC 256 mg L⁻¹), while control isolates containing the WT region displayed a median MIC of 8 mg L⁻¹ (Supplementary Figure 2). The correlation between rifampicin and daptomycin resistance in clinical strains containing the G482D, H486Y, and S491F mutations, suggested a novel link between rifamycin and daptomycin resistance in VREfm.

To confirm the G482D and H486Y mutations in RpoB also led to rifamycin and daptomycin resistance we constructed isogenic mutants carrying these mutations in the same rifamycinsusceptible, daptomycin-susceptible, clinical strain of VREfm (ST796), used to make the S491F RpoB isogenic mutant above. Introduction of the G482D, H486Y, or S491F RpoB mutations resulted in a 7-fold decrease in rifampicin susceptibility compared to the WT strain, leading to high-level rifampicin resistance (>512 mg L⁻¹) (Figure 1D). To confirm the changes in rifampicin susceptibility were due to the introduction of each specific mutation and not unknown secondary mutations, we reverted each RpoB mutation to WT by restoration of the chromosomal allele. Complementation to the WT rpoB allele in each of the G482D, H486Y, or S491F mutants resulted in reversion of rifampicin MIC to the WT level (8 mg L⁻¹), indicating the RpoB mutations were responsible for the heightened levels of rifampicin resistance observed (Figure 1D). To then determine if the G482D and H486Y mutations could also cause daptomycin resistance, daptomycin susceptibility testing was performed. Similar to the S491F isogenic strain, introduction of the G482D or H486Y mutation resulted in a 4-fold increase in daptomycin MIC, from 2 mg L⁻¹ to 8 mg L⁻¹, and a daptomycin-resistant phenotype (Figure 1E). Complementation with the WT rpoB allele onto the chromosome resulted in reversion of daptomycin MIC to the WT level, indicating the G482D, H486Y, and S491F RpoB mutations resulted in cross-resistance to rifamycins and daptomycin in VREfm.

Given the reported importance of *liaRS* mutations in daptomycin-resistant VREfm, we also introduced the well-characterised LiaR W73C and LiaS T12OA mutations into the same clinical strain of VREfm (Figure 1D). No difference in rifampicin MIC was observed after introduction of the *liaRS* mutations, compared to the WT strain, indicating the cross-resistance observed with the G482D, H486Y, and S491F mutations is unique to these RpoB substitutions. However, compared to the WT, introduction of the *liaRS* mutations decreased daptomycin susceptibility 2-fold, with a reversion to the WT daptomycin MIC after complementation with the WT *liaRS* alleles. The introduction of the *liaRS* mutations had less of an impact on daptomycin susceptibility than the G482D, H486Y, and S491F RpoB mutations and did not result in a daptomycin-resistant phenotype (MIC ≥8 mg L⁻¹). When considered in conjunction with the genomic epidemiology data associated with this study, where *liaRS* mutations were less common than the *rpoB* mutations in daptomycin-resistant VREfm (n=7 versus n=141, respectively), our data suggests that mutations within RpoB might represent a previously uncharacterised, yet important mechanism of daptomycin resistance in VREfm.

The G482D, H486Y and S491F RpoB mutations are common in international VREfm strains.

To determine if the *rpoB* mutations associated with daptomycin resistance observed in Australian VREfm were representative of other VREfm isolates globally, we performed a large-scale analysis using publicly available VREfm sequence data from healthcare-associated strains (n=4,476; n=3,476 international and n=1,000 Australian) (Figure 2A). Of the isolates analysed, 630 (14.3%) carried an amino acid substitution in the RRDR of RpoB, occurring at 16

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

positions (Figure 2B). The S491F mutation was the most common, being present in 461 isolates, and accounting for 77.9% of the RpoB mutations observed. Isolates carrying this mutation originated from 20 countries, and in silico MLST showed the mutations were spread across 21 different STs, with ST203 (44.7%), ST80 (30.2%), and ST117 (11.5%) accounting for the majority (86.4%) of isolates carrying this substitution. Importantly, five VREfm harbouring the S491F mutation also contained the cfr(B) (n=4) or poxtA (n=1) genes that confer resistance to linezolid, suggesting near pan-resistant strains of VREfm have already emerged. The H486Y mutation was the second most common, and was identified in 73 isolates, equivalent to 11.6% of strains with mutations within the RRDR of RpoB. These isolates were collected from 10 countries and in silico MLST identified 22 STs, with the most common being ST203 (23.2%), ST796 (21.9%), and ST80 (20.5%). The G482D mutation was the third most common, being identified in 43 isolates, and accounting for 6.8% of strains carrying RpoB mutations. It was present in nine distinct STs, although mostly commonly in ST796 (65.1%) and ST1421 (11.6%), and was identified in isolates from seven countries. Collectively, these data indicated the G482D, H486Y, and S491F mutations, which confer cross-resistance to rifamycins and daptomycin, are not restricted to Australian VREfm but are globally prevalent in healthcare-associated VREfm strains. To determine whether the identified RpoB mutations were enriched within healthcareassociated VREfm (established as clade A1), we interrogated publicly available genomic sequences of VREfm from clade A2 (n=98), known for being animal-associated²⁷. In keeping with previous findings, the maximum-likelihood tree clustered isolates into two main clades: one healthcare-associated and one associated with VREfm from animals. No mutations were

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

identified in the RpoB RRDR region of strains isolated from animals, with our analyses showing that RRDR RpoB mutations were significantly (P<0.001; Fisher's exact test) associated with healthcare-associated VREfm. This suggests the identified RpoB mutations are primarily enriched within the healthcare setting (Supplementary Figure 3). Phylodynamics indicate the S491F RpoB mutation emerged within the VREfm population following the clinical approval of rifaximin. Given the predominance of the S491F mutation in globally distributed VREfm populations, we used evolutionary phylodynamic analyses to understand its emergence. Within our Australian isolates, we observed the expansion of a dominant ST203 clone from 2015 to 2018 that carried the S491F mutation (Figure 1C). Since this clone comprised VREfm carrying the vanA resistance cluster or operon, we sequenced all "historical" vanA-VREfm from our public health laboratory (n=229), which consisted of every vanA-VREfm isolate collected from 2003 to 2014, to increase temporal signal. We then contextualised all Australian isolates (n=1,229) with the international (n=3,389) VREfm in a maximum-likelihood phylogeny inferred from an alignment of 9,277 SNPs and used clustering with core-genome MLST (cgMLST) to identify three clusters containing the RpoB S491F mutation (Figure 3A). The same ST203 clone (Cluster 1) formed the largest cluster (n=219 taxa), consisting of isolates from Australia and United Kingdom. Cluster 2 (n=85 taxa) consisted of ST80 and ST78 isolates from Australia, Europe, South America, the United Kingdom, and the United States of America while Cluster 3 (n=68 taxa) consisted of ST80 isolates from Australia, Europe, and the United Kingdom. To model the evolutionary trajectories of these three VREfm clusters, we used core-genome

SNP diversity and year of isolation (Figure 3B). Bayesian phylodynamic analyses were

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

conducted using the core-genome SNP alignments for each cluster/lineage with a discrete trait model and constant coalescent tree prior. We assessed for temporal signal within each cluster using a root-to-tip regression (Supplementary Figure 4). The substitution rate (the number of expected substitutions per site per year) was consistent with other estimates for healthcare-associated VREfm, otherwise referred to as clade A1^{27–30}. The median substitution rate was similar for Cluster 1 and Cluster 2, at 9.7x10⁻⁷ [95% highest posterior density (HPD) $6.88 \times 10^{-7} - 1.24 \times 10^{-6}$] and 1.25×10^{-6} (95% HPD $7.68 \times 10^{-7} - 1.74 \times 10^{-6}$) respectively, but slightly faster for Cluster 3 at 3.86×10^{-6} (95% HPD $2.23 \times 10^{-6} - 5.69 \times 10^{-6}$). The year of emergence for the most recent common ancestor (MRCA) was estimated for each cluster to indicate when the RpoB S491F mutation was first acquired. The MRCAs for the clusters were similar, with 2006 (HPD 1993 – 2012) for Cluster 1, 2000 (HPD 1989 – 2008) for Cluster 2, and 2004 (HPD 2001 – 2010) for Cluster 3, suggesting the lineages emerged at similar times (Figure 3C). Given the association of the S491F mutation in RpoB and rifamycin resistance, we hypothesised rifamycin use might be driving the emergence of this mutation. The most commonly used rifamycin antibiotics in clinical practice are rifampicin and rifaximin. Since rifampicin was approved for clinical use by the United States Federal Drug Administration (FDA) in 1971, several decades before the estimated emergence of the MRCAs, it is unlikely to have played a major role in the emergence of the S491F mutation within this VREfm population. However, the MRCA for all three clusters is predicted to have emerged around the same time as the first clinical introduction of rifaximin, in 2004. The acquisition of the same mutation in three genetically distinct lineages at a similar time, provides support for our hypothesis that rifamycin use might be driving selection of the S491F mutation within VREfm. Further, the structure of the three maximum clade credibility (MCC) trees (Figure 3B) suggested the lineages have expanded over time, which may be correlated with the approval and subsequent widespread, international use of rifaximin for the prevention of hepatic encephalopathy since 2010 (Figure 3B).

The S491F mutation in Cluster 1 and Cluster 2 was found to be stably maintained within each lineage after its acquisition, with few high probability events of reversion to the WT *rpoB* allele, indicative of maintenance after emergence (Supplementary Figure 5A-B). For Cluster 3, the RpoB S491F mutation emerged a single time, with high (~0.95) posterior probability of a single acquisition within the cluster and subsequent maintenance (Supplementary Figure 5C). There was also an equal posterior probability of either a second acquisition within the cluster or loss of the RpoB S491F mutation within Cluster 3. Overall, the Markov jumps for all three clusters suggests that the S491F mutation emerged and was then subsequently maintained within these globally prevalent lineages. Taken together these data show the S491F mutation has emerged within the VREfm population on several occasions since the early 2000s, with the predicted dates of emergence being closely correlated with the clinical introduction of rifaximin.

Rifaximin drives the emergence of daptomycin-resistant VREfm in a murine model of gastrointestinal colonisation.

Rifaximin is a non-absorbable oral agent with direct antimicrobial activity in the gastrointestinal tract. It is predominately used to prevent recurrent hepatic encephalopathy in patients with liver cirrhosis^{18,31}. Importantly, this patient cohort is high-risk for VREfm colonisation within the gastrointestinal tract³². Since the Bayesian phylodynamic analyses highlighted a putative correlation between the S491F RpoB mutation in VREfm and use of

rifaximin, we hypothesised rifaximin use may be driving the emergence of this mutation and therefore, daptomycin-resistant VREfm within the gastrointestinal tract of patients receiving this antibiotic. To test this hypothesis, mice were colonised with a clinical, daptomycin-sensitive (MIC 2 mg L⁻¹) VREfm strain (Aus0233) containing a WT rpoB gene before being administered a human-equivalent dose of rifaximin, rifampicin, daptomycin, or vehicle (Figure 4A and Supplementary Figure 6). Rifampicin was chosen as a comparison since it is also a commonly used rifamycin in clinical practice. After 7 days of rifamycin treatment, we observed rifamycin-resistant VREfm in significantly more mice receiving rifaximin (90% of mice) or rifampicin (80% of mice) than in mice that received daptomycin (0% of mice) (P < 0.0001 and P < 0.0001; unpaired t-test) or vehicle (0% of mice) (P < 0.0001 and P < 0.0001; unpaired t-test) or vehicle (0% of mice) (P < 0.0001 and P < 0.0001; unpaired t-test) (Figure 4B).

For each mouse, we then determined the percentage of individual VREfm isolates that were rifamycin-resistant or daptomycin-resistant. There were significantly more rifamycin-resistant VREfm isolated from mice receiving rifaximin or rifampicin than mice receiving the vehicle control (P < 0.001 and P < 0.01; unpaired t-test) or daptomycin (P < 0.001 and P < 0.01; unpaired t-test) (Figure 4D). Similarly, there was significantly more daptomycin-resistant VREfm in mice receiving rifaximin or rifampicin than vehicle control (P < 0.05 and P < 0.05; unpaired t-test) or daptomycin (P < 0.05 and P < 0.05; unpaired t-test) (Figure 4E). We estimated that daptomycin-resistant VREfm accounted for between 0-41% of the gastrointestinal VREfm population in mice given rifaximin and 0-36% in mice given rifampicin, demonstrating conclusively that rifamycin administration can drive the emergence of VREfm with cross-resistance to rifamycins and daptomycin. Notably, no daptomycin-resistant VREfm were isolated from mice receiving daptomycin, in agreement with prior research³³.

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

To identify which mutations were present in the rifamycin-resistant VREfm isolates collected from mice administrated either rifaximin or rifampicin, we randomly selected 150 isolates from each antibiotic group (rifaximin or rifampicin, n=300 total) to undergo WGS, consisting of 100 rifamycin-resistant isolates collected following the last day of treatment and 50 isolates from before rifaximin or rifampicin administration. No mutations in RpoB were identified in any VREfm isolate collected prior to rifaximin or rifampicin exposure. However, following the administration of either rifaximin or rifampicin, VREfm carrying mutations within RpoB were commonly identified. The S491F mutation was most abundant (n=53 and 63, respectively), with all isolates carrying this mutation being daptomycin-resistant (Figure 4F). The H486Y mutation was also commonly identified, albeit less so than S491F, (n=12 and 28, respectively), with all isolates again being daptomycin-resistant. The G482D mutation was the third most commonly identified RpoB mutation (n=15 and 6, respectively), with 13 isolates carrying this mutation being daptomycin-resistant. Note that 2 isolates containing the G482D mutation in the rifampicin treated mice were daptomycin-sensitive, likely due to other confounding mutations within the genome. Other RpoB mutations in addition to S491F, H486Y, and G482D were also identified. These included V135F, L471V, E473L, and H486A, however all VREfm isolates carrying these mutations were daptomycin-sensitive. Importantly, the proportions of each RpoB mutation observed in VREfm collected from the gastrointestinal tract of mice administered either rifaximin or rifampicin, correlated closely the proportions of each mutation observed in our collection of human clinical VREfm isolates, with the S491F mutation most commonly identified, followed by H486Y, and then G482D, suggesting a similar selective pressure (i.e. rifamycin use) found in our mouse experiments might be driving the emergence of similar RpoB mutations within human clinical isolates. Taken together,

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

these data demonstrate that exposure to rifaximin can drive the emergence of daptomycin resistance in colonising strains of VREfm, through the enrichment of isolates carrying select mutations in RpoB. VREfm collected from patients receiving rifaximin are more likely to be daptomycinresistant than VREfm collected from patients that did not receive rifaximin. To further test our hypothesis that rifaximin use might be driving the emergence of daptomycin resistance in VREfm, we performed a case-control analysis of clinical VREfm isolates collected from a retrospective cohort of patients from a single tertiary healthcare centre in Melbourne, Australia over 4 years. The VREfm isolates were stratified according to whether the patient had received rifaximin within 1 month of VREfm isolate collection or not. A total of 50 VREfm strains were identified as being from patients receiving rifaximin. As a control group, we randomly selected 50 VREfm that had been collected from patients that had not received rifaximin. The majority (88%) of these VREfm were screening samples. All isolates were collected over the same time frame and from the same institution. A maximum-likelihood phylogeny was inferred from an alignment of 12,430 core-genome SNPs (Figure 5A). The VREfm isolates in the rifaximin and control groups were dispersed throughout the tree, with 5 different STs (ST78, ST80, ST203, ST796, ST1421, and ST1424) from rifaximin patients and 6 different STs (ST17, ST78, ST80, ST203, ST796, ST1421, and ST1424) from the control patients. There were 28 VREfm from the rifaximin group that contained a mutation within the RRDR of RpoB, with 17 containing the S491F mutation, 5 G482D, 4 H486Y, 1 E473L, and 1 G482V mutation. All isolates containing the S491F, H486Y, and G482D mutations were resistant to daptomycin, while isolates with the E473L and G482V mutations were daptomycin-susceptible. The control group had 2 isolates with RRDR RpoB mutations, with 1 susceptible isolate containing a D476Y and 1 daptomycin-resistant isolate containing the S491F substitution.

Rifaximin exposure in patients was significantly correlated with the isolation of a rifamycin-resistant (P = 0.00007, OR = 60.0, 95% CI = 8.8 - 2562.1; Fisher's Exact Test) and daptomycin-resistant VREfm strain (P = 0.0006, OR = 25.0, 95% CI = 5.5 - 235.3; Fisher's exact test) (Figure 5B and C). These data indicated that patients receiving rifaximin are significantly more likely to carry rifamycin-resistant and daptomycin-resistant strains of VREfm than patients who did not receive rifaximin, suggesting rifaximin use might be an important driver in the *de novo* emergence and spread of daptomycin-resistant VREfm.

Discussion

In this study we have shown that specific mutations within the RRDR of RpoB represent a new, major mechanism of daptomycin resistance in VREfm. Our analyses demonstrate these mutations are globally distributed within the VREfm population and are as prevalent as other well-characterised mutations within LiaRS and Cls, which have been previously associated with daptomycin resistance in VREfm and assumed to be the dominant mechanisms^{22,34,35}. Given the similar prevalence, as well as the finding that isogenic mutants carrying the G482D, H486Y or S491F RpoB mutations display a greater level of daptomycin resistance than isogenic strains carrying mutations in LiaRS, the RpoB mutations discovered here add to the list of clinically relevant mutations involved in the emergence of daptomycin-resistant VREfm.

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

Our data suggest the S491F substitution is the dominant RRDR RpoB mutation in VREfm and is present in at least three phylogenetically distinct lineages currently circulating within healthcare systems globally, including in Australia, the United Kingdom, the United States of America, and across Europe. The extent of their dissemination is likely to be underestimated in regions with limited representation in our analyses, such as in Asia, Africa, and South America. It is of clinical concern these lineages have successfully spread over geographic scales and persisted for at least 15 years, since it suggests these globally prevalent lineages might eventually compromise the therapeutic value of daptomycin for treating VREfm infections. The Bayesian analyses provide support the S491F mutation emerged after the first introduction of rifaximin for clinical use, for treatment of travellers' diarrhea, with each of the MCC trees suggestive of subsequent population expansion. In 2010, rifaximin was shown to be efficacious for the prevention of recurrent hepatic encephalopathy in patients with chronic liver disease 18 resulting in a marked increase in its clinical use. As this patient cohort is predisposed to gastrointestinal VREfm colonisation, we hypothesise that the use of rifaximin in this cohort has driven the population expansion of the S491F mutation in VREfm over subsequent years. Further, our data suggests rifampicin is not a significant driver of these RpoB mutations since therapeutic use of rifampicin has occurred since the 1970s and the emergence of VREfm containing these mutations is much more recent. However, appropriately controlled clinical cohort studies will be needed to test these hypotheses. VREfm isolates carrying the G428D, H486Y and S491F RpoB mutations were resistant to rifamycin antimicrobials, in addition to daptomycin. Mutations within the RRDR of RpoB have been associated with rifamycin resistance in numerous bacterial species²⁶, with exposure to rifamycins being a well-documented driver in the emergence of rifamycin-resistant clones in

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

Staphylococcus^{36–38}. In keeping with this observation, our data suggests the clinical use of rifaximin may be responsible for selecting VREfm isolates harbouring mutations within the RRDR of RpoB and therefore, indirectly driving the emergence of daptomycin-resistant VREfm. Three lines of evidence support our hypothesis: (i) Bayesian phylodynamic analyses show the emergence of phylogenetically distinct VREfm lineages carrying the S491F is temporally linked with the clinical approval of rifaximin in the early 2000s, (ii) animal experiments demonstrated the administration of rifaximin to mice colonised with VREfm led to the emergence of VREfm strains within the gastrointestinal tract that carried mutations within RRDR of RpoB and were resistant to rifamycins and daptomycin, and (iii) an analysis of clinical VREfm isolated from humans showed patients receiving rifaximin were significantly more likely to carry VREfm strains harbouring mutations within the RRDR of RpoB that were resistant to both rifamycins and daptomycin, compared to patients that did not receive rifaximin. It is therefore plausible that rifaximin exposure in this patient cohort might be an important factor in the increasing rates of daptomycin-resistant VREfm that are currently being reported^{17,39}, through the *de novo* emergence of the RpoB mutations and/or ongoing transmission of resistant strains carrying these mutations. Appropriately controlled clinical cohort studies are needed to dissect this hypothesis. Importantly, given the high rates of daptomycin resistance observed, our results suggest daptomycin should not be used for empiric therapy of invasive VREfm infections in patients who are receiving rifaximin.

Of note is our observation that rifaximin exposure in mice led to the emergence of strains carrying similar RRDR RpoB mutations to those observed in human clinical isolates and the relative abundance of these mutations within isolates collected from the gastrointestinal tract of mice exposed to rifaximin closely resembled the relative abundance of these mutations in

our collection of human VREfm, with S491F, G482D and H486Y being the most abundant mutations in both cases. These observations are suggestive of similar selective pressures, such as rifaximin exposure, being at play in both the controlled mouse experiments of our study and in the human population.

Overall, this research highlights the potentially serious collateral damage that can arise following the introduction of new clinical antibiotic regimens. While the emergence of withinfamily antibiotic resistance resulting from prophylactic antibiotic use has been described previously^{40,41}, there are relatively few studies³⁷ suggesting that prophylactic antibiotics, such as rifaximin, can lead to cross-resistance between unrelated and last-resort antibiotics, as shown here. Careful consideration should therefore be given to the potential impact of prophylactic antibiotics on antimicrobial stewardship practices. Current thinking⁴² recommends withholding the use of last-resort antibiotics to limit the emergence and spread of resistance. However, our findings suggest this is not always the case, since gastrointestinal rifaximin exposure can lead to the emergence of daptomycin-resistant VREfm in the absence of daptomycin. Appropriate surveillance for patients colonised in the gastrointestinal tract with nosocomial pathogens and receiving antibiotic treatment for secondary or unrelated conditions is therefore of critical importance in limiting the emergence and spread of new and increasingly antibiotic-resistant clones within the hospital environment.

In conclusion, we have identified a new, globally important mechanism of last-resort antibiotic resistance in VREfm and show that prophylactic rifaximin use is a likely driver of this resistance. These findings demonstrate the ease with which new antibiotic treatment regiments can drive the emergence of novel multidrug resistant pathogens and highlight the

negative impact that unanticipated antibiotic cross-resistance can have on antibiotic stewardship efforts designed to preserve the use of last-resort antibiotics. We advocate for the judicious use of all antibiotics.

Methods

Media and reagents

E. faecium was routinely cultured at 37°C in brain heart infusion (BHI) broth (Becton Dickson) or BHI agar (BHIA), BHI solidified with 1.5% agar (Becto Dickson). For electroporation, E. faecium was cultured in BHI supplemented with 3% glycine and 200 mM sucrose (pH 7.0). Escherichia coli was cultured in Luria broth (LB). Broth microdilution (BMD) MICs were performed in cation-adjusted Mueller Hinton with TES broth (CAMHBT) broth (Thermo Fisher). A concentration of 10 mg L¹ chloramphenicol (Sigma Aldrich) was used for plasmid selection in E. faecium and E. coli. The following antibiotics were used at variable concentrations for susceptibility testing: rifampicin (Sigma Aldrich), rifaximin (Sigma Aldrich), and daptomycin (Cubicin).

Oligonucleotides were purchased from Integrated DNA Technologies and are listed in Supplementary Table 1. Plasmids were purified with Monarch Plasmid Miniprep Kit (NEB). PCR products and gel extractions were purified using Monarch DNA Gel Extraction Kit (NEB). Genomic DNA was purified using the Monarch Genomic DNA Purification Kit (NEB). Phusion and Phire DNA polymerase was purchased from New England Biolabs.

Bacterial isolates

Bacterial strains used in this study are listed in Supplementary Table 2. Australian bacterial strains were collected across three data projects in the Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL). Two unbiased cross-sectional surveys of VREfm were conducted between 10 November and 9 December 2015 (n=331)⁴³ and between 1 November and 30 November 2018 (n=323) in the State of Victoria (referred to as the 2015 and 2018 Snapshot). During this period, all VREfm-positive isolates (including screening and clinical samples) collected by laboratories across the state were sent to the MDU PHL. In addition,

this project included vanA-VREfm collected from the "Controlling Superbugs" study²⁰, a 15month (April-June 2017 and October 2017-2018) prospective study including eight hospital sites across four hospital networks, resulting in 346 VREfm isolates (308 patients) sent for WGS at MDU PHL. The VREfm were isolated from patient samples (including screening and clinical samples) routinely collected from hospital inpatients. For the 'historical vanA-VREfm,' every vanA isolate collected within MDU PHL was included. This resulted in an additional 225 isolates, sampled between 2008 and 2014. For publicly available isolates, our aim was to capture the diversity of *E. faecium* circulating globally by including isolates that formed part of several key studies involving hospitalassociated VREfm (as of January 2021). To be included, isolates needed to have short-read data available, with geographic location (by country), year of collection, and source (human or animal). Reads were only included if they had a sequencing depth of >50x. To capture the diversity of VREfm circulating in the United States, isolates from human sources were downloaded from the PathoSystems Resource Integration Center⁴⁴. All isolates were confirmed to be E. faecium with the Kraken2 database (v.2.1.2)45. The final number of international isolates compromised those from Africa (n=8), Asia (n=25), Europe (n=2941), North America (n=424), and South America (n=78) (Supplementary Table 2).

Antibiotic susceptibility testing

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

Daptomycin susceptibility testing was performed using the BMD MIC method as according to CLSI guidelines. In a 96-well plate, a two-fold dilution series (from 32 to 0.5 mg L^{-1}) of daptomycin was made in 100 μ L volumes of CAMHBT, additionally supplemented with 50 mg L^{-1} Ca²⁺. An inoculum of 100 μ L *E. faecium* broth culture adjusted to 1 x 10⁶ CFU mL⁻¹ in CAMHBT was then added to each well. After 24 hours incubation, the MIC was defined as the lowest antimicrobial concentration that inhibited visible growth. All assays were performed

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

in biological triplicate, with the median MIC reported. In accordance with recent guidelines⁴⁶, isolates with a daptomycin MIC \geq 8 mg L⁻¹ were considered to be daptomycin-resistant. A daptomycin-sensitive strain (AUS0085)⁴⁷ and a daptomycin-resistant strain (DMG1700661)¹⁷ were used as a control. Rifampicin susceptibility testing was performed using the BMD method in CAMHBT. Highlevel rifampicin resistance was defined with a MIC > 32 mg L⁻¹. All susceptibility testing was performed in triplicate. Whole-genome sequencing Genomic DNA was extracted from a single colony using a JANUS automated workstation (PerkinElmer) and Chemagic magnetic bead technology (PerkinElmer). Genomic DNA libraries were prepared using the Nextera XT kit according to manufacturer's instructions (Illumina, San Diego, CA, USA). Whole-genome sequencing was performed using Illumina NextSeq platform, generating 150 bp paired-end reads. The short reads of isolates sequenced at MDU-PHL are available on the NCBI Sequence Read Archive [BioProjects PRJNA565795 (Controlling Superbugs), PRJNA433676 (2015 Snapshot) and PRJNA856406 (2018 Snapshot), and PRJNA856406 (historical vanA isolates)]. Phylogenetic analysis De novo assemblies of the genomes were constructed using Spades⁴⁸ (v3.13). In silico MLST determined using the mlst with the efaecium database were program (https://github.com/tseemann/mlst). The 1000 Australian genomes as well as the 4,612 Australian and international VREfm were mapped to the reference E. faecium genome AUS0085 isolated from a human bacteraemia infection in Victoria, Australia (NCBI accession: CP006620)⁴⁷ using snippy (https://github.com/tseemann/snippy) (v4.4.5), applying a minfrac value of 10 and mincov value of 0.9. This reference was selected as it was a publicly available

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

complete genome collected locally and daptomycin-sensitive. A maximum likelihood phylogenetic tree was inferred using IQ-TREE (v2.1.2) with a general time-reversible (GTR + G4) substitution model, including invariable sites as a constant pattern and 1000 bootstrap replicates. Recombination masking was not performed for species maximum likelihood trees due to the small size of the resulting core alignment. All trees were mid-point rooted and visualised in R (v4.0.3, https://www.r-project.org/) using phangorn⁴⁹ (v2.5.5), ape⁵⁰ (v5.4), ggtree⁵¹ (v2.3.4), and ggplot (v3.3.2). The genome assemblies of all isolates were screened for acquired antimicrobial resistance determinants using abriTAMR (https://github.com/MDU-PHL/abritamr). Genome-wide association study of daptomycin resistance A GWAS approach was applied to identify genetic variants of daptomycin resistance in E. faecium. A genotype matrix of SNPs was constructed and used as input to homoplasyFinder⁵² (v0.0.0.9) to determine the consistency index at each locus and kept mutations that had an index of ≤0.5 (indicating at least two independent acquisitions across the phylogeny). We then ran GWAS using daptomycin resistance as a binary trait, where isolates were categorised as resistant if their daptomycin MIC was ≥8 mg L⁻¹. To correct for population structure, we used the factored spectrally transformed linear mixed models (FaST-LMM) implemented in pyseer⁵³ (v.1.3.6), which computes a kinship matrix based on the core genome SNPs as a random effect. The Bonferroni method was used to correct P values for multiple testing. Core genome MLST (cgMLST) and clustering cgMLST alleles for each isolate was defined using the public E. faecium cgMLST scheme⁵⁴ and chewBBACA (v2.0.16), implemented locally in the COREugate pipeline (v2.0.4) (https://github.com/kristyhoran/Coreugate). The pipeline determines the alleles of each core gene for every isolate as defined by the specific pathogen scheme. The E. faecium cgMLST

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

scheme contains 1,423 genes. The number of allelic differences between each isolate within this core set of genes is then determined. The cgMLST clusters were determined using single linkage clustering and a pairwise allelic difference threshold of ≤250. This threshold was chosen since it maximised diversity within clusters, to improve temporal sampling depth, while still clustering based on maximum-likelihood tree structure. Phylodynamic analyses of the emergence of the S491F RpoB mutation in VREfm lineages To investigate the emergence of the S491F mutation in RpoB in three different lineages, as defined with cgMLST, we undertook further analysis on these clusters/lineages. From the species-level maximum-likelihood tree (Figure 3A), three lineages/clusters were identifiable by cgMLST due to their size (n>50) and presence of the S491F mutation. The three clusters were analysed independently, such that individual core-genome SNP alignments were generated, since this increased the length of the core alignment and number of sites considered. Snippy (https://github.com/tseemann/snippy) (v4.4.5) was used to generate the alignments for each cluster to the corresponding reference genome (AUSMDU00004024 for cluster 1, AUSMDU00004055 for cluster 2, and AUSMDU00004142 for cluster 3). Each core alignment used a within 'cluster reference' (complete genome of the same cluster) to maximise core-SNP alignment length. The reference for each cluster was chosen since they were a locally-collected, closed genome. Recombination was removed from the final alignment using Gubbins⁵⁵ (v.2.4.1) to ensure modelling was only informed by SNPs with treelike evolution within the core genome. Maximum-likelihood trees for each of the three clusters were inferred from the core-SNP alignments [Cluster 1: (n=219 taxa) 329 SNPs; Cluster 2: (n=85 taxa) 541 SNPs; Cluster 3: (n=68 taxa) 764 SNPs] with IQ-tree (v2.1.2)⁵⁶ with a general time-reversible (GTR+ Γ) substitution model, including invariable sites as a constant pattern. Phylogenetic uncertainty was determined through 1000 nonparametric bootstrap replicates.

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

To investigate temporal signal in the three clusters of VREfm genomes, we first used TempEst⁵⁷ (v1.5). A root-to-tip regression analysis was performed on the root-to-tip branch distances within the three, cluster maximum-likelihood phylogenies as a function of year of collection, with the position of the root optimised according to the heuristic residual mean squared method.

The frequency of the emergence of the rpoB mutation in VREfm was inferred using a discrete trait model implemented in BEAST⁵⁸ (v1.10.4). Under this model the SNP alignments are used to infer the evolutionary process (i.e. phylogenetic tree, time, and nucleotide substitution model parameters) for the three clusters. The alignments all shared the HKY substitution model with a gamma distribution for among-site rate variation, and a constantsize coalescent population prior²⁸. To avoid ascertainment bias due to using a SNP alignment, the number of constant sites were taken into account for the likelihood calculations. The molecular clock was a relaxed clock with an underlying lognormal distribution. The molecular clock was calibrated using isolation dates for each genome by year of collection and the mean clock rate is shared between all three alignments, but the model allows for the individual alignments to have different standard deviations of the lognormal distribution and also different branch rates. The mean molecular clock rate requires an explicit prior distribution, for which we used a Γ distribution and a 0.95 quantile range of 4.9x10⁻⁶ and 1.1x10⁻⁴ substitutions/site/year. This informative prior means that it acts as an additional source of molecular clock calibration that can drive estimates, even in the absence of temporal signal.

The presence or absence of the S491F mutation in *rpoB* was used as a binary trait^{59,60}.

The trait model was shared between the three alignments, with the different Markov jumps

and rewards (ie changes of trait state and time spent in each state, respectively) recorded for each of the three alignments. The posterior distribution of model parameters was sampled using a Markov chain Monte Carlo of 100,000,000 iterations, sampling every 100,000 iterations. Two independent runs were run for the models. We assessed sufficient sampling from the stationary distributions by verifying the effective sample size of key parameters was around or above 200. The final maximum-clade credibility (MCC) trees were visualised in R (v4.0.3, https://www.r-project.org/) using ggtree⁵¹ (v2.3.4). The Markov jumps for the *rpoB* trait for each alignment were visualised in R (v4.0.3, https://www.r-project.org/).

Reconstruction of clinical mutations by allelic exchange

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

The liaR^{W73C}, liaS^{T120A}, rpoC^{T634K}, rpoB^{G482D}, rpoB^{H486Y}, or rpoB^{S491F} mutations were recombined into the chromosomal copy of each gene in ST796 VREfm (Ef aus0233) by allelic exchange. The liaRW73C and liaST120A mutations were first introduced individually, then together. The region encompassing each gene was amplified by SOE-PCR and recombined into pIMAY-Z⁶¹ by the seamless ligation cloning extract (SLiCE)⁶² method and transformed into Escherichia coli IM08B⁶¹. The construct was transformed into electrocompetent VREfm⁶², with allelic exchange performed as described previously⁶³. Allelic exchange was performed as described⁶³. Reversion of *liaR*^{W73C} and *liaS*^{T120A}, *rpoB*^{G482D}, *rpoB*^{H486Y}, or *rpoB*^{S491F} mutations were completed using allelic exchange with a construct containing the respective wild-type allele. To delete the ABC transporter protein (EFAU085 02633), permease protein (EFAU02892), or mannitol dehydrogenase (EFAU02627) from the chromosome, deletion constructs were PCR-amplified from Ef_aus0233 genomic DNA and allelic exchange performed as described above. Genome sequencing and analysis of all mutants was conducted as described, with resulting reads mapped to the Ef aus0233 reference genome and mutations identified using Snippy (https://github.com/tseemann/snippy) (v4.4.5).

VREfm in vivo gastrointestinal colonisation experiments

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

Female C57BL/6 mice at 6-8 weeks of age were purchased from WEHI and maintained in a specific-pathogen-free facility at the Peter Doherty Institute for Infection and Immunity. All animal handling and procedures were performed in a biosafety class 2 cabinet. Animal procedures were performed in compliance with the University of Melbourne guidelines and approved by the University's Animal Ethics Committee The dose for each antibiotic was calculated using the FDA human conversion formula to ensure each mouse was given a human-equivalent dose⁶⁴. To establish gastrointestinal colonisation of VREfm, mice were administered ceftriaxone (410 mg kg⁻¹ day⁻¹; AFT Pharmaceuticals) via subcutaneous injection once daily for 7 days, followed by an antibiotic wean period of 24 hours. Mice were then inoculated with 10⁶ VREfm in 100 μl PBS by oral gavage. Three days after VREfm inoculation, single-housed mice were administered either rifaximin (113 mg kg⁻¹ administered twice daily; Sigma Aldrich), rifampicin (123 mg kg⁻¹ administered once day; Sigma Aldrich), or vehicle (Corn oil with 10% DMSO) via oral gavage; or daptomycin (50 mg kg⁻¹ administered once daily; Cubicin) via subcutaneous injection [this results in similar exposure (AUC₀₋₂₄) to that observed in humans receiving 8 mg kg⁻¹ of intravenous daptomycin⁶⁵]. The above antibiotic dosing protocol was followed for 7 days. Faecal samples were collected at specific time points throughout the experiment to determine VREfm gut colonisation and for downstream rifamycin and daptomycin resistance analysis. Faecal samples were resuspended in PBS to a normalised concentration (100 mg ml 1). Serial dilutions were performed, and samples were plated onto Brilliance VRE agar (Oxiod) for VREfm CFU enumeration. For rifamycin and daptomycin analysis, VREfm colonies (n=50 per mouse) from the Brilliance VRE agar plates were replica plated onto BHIA with and without rifampicin 20 mg mL⁻¹ to determine the proportion of rifampicin-resistant VREfm in each mouse. All colonies (n=50 per mouse) were then screened for daptomycin resistance using a daptomycin screen. Of which, a single colony was resuspended in PBS, then diluted 1/100 into CAMHBT containing 50 mg L⁻¹ Ca²⁺, and 1/100 in MH containing 50 mg L⁻¹ Ca²⁺, and 8 mg L⁻¹ daptomycin. All suspected daptomycin-resistant colonies were confirmed using a daptomycin BMD MIC as before. To determine which mutations were present in the rifamycin-resistant isolates, a random selection of 300 colonies, 150 from rifaximin treated mice and 150 from rifampicin treated mice, were sampled for WGS as described above.

Analysis of VREfm isolates from patients receiving rifaximin.

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

To examine the potential association of rifaximin use in humans and the presence of daptomycin-resistant VREfm strains, we analysed VREfm collected between 2018 and 2021 from a single hospital institution in Melbourne. These isolates underwent WGS and daptomycin and rifampicin susceptibility testing as before. Isolates were stratified according to whether the patient received rifaximin within 1 month of VREfm isolation or remained rifaximin free prior to isolate collection. The majority (80%) of isolates were routine screening samples. This included 50 VREfm isolates from patients receiving or previously receiving rifaximin at time of isolation, which were randomly matched to 50 VREfm isolates from patients not receiving rifaximin administration. All isolates were collected within the same time frame. The VREfm isolates were visualised in a maximum-likelihood phylogenetic tree as before, using a core-SNP alignment of 12,430 sites. Isolate MLST was defined with the mlst tool mutations determined and in RpoB were using Snippy (https://github.com/tseemann/snippy) (v4.4.5) as described.

Data visualisation and statistics

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

All figures were generated in R (v4.0.3, https://www.r-project.org/) using tidyverse (v.1.3.1), patchwork (v.1.1.1), and ggnewscale (v.0.4.5). Statistical analyses were performed using R (v4.0.3, https://www.r-project.org/) and GraphPad Prism (v9.3.1) software packages. Specific tests are given together with each result in the text. **Ethics approval** Ethical approval for analysis of patient data was received from the University of Melbourne Human Research Ethics Committee (study number 1954615.3). **Competing Interests** The authors declare no competing interests. **Acknowledgements** This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant (GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT and NLS are supported by an Australian Government Research Training Program scholarship. The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance (funded by the State Government of Victoria, Department of Health and Human Services, and the 10 member organizations). **Author Contributions** GPC, BPH, and CLG conceived and planned the experiments. AMT, LL, IRM, DLI, SD, and GPC performed the planned experiments. JCK provided access to necessary patient metadata and clinical VREfm isolates that were used in the study. JYHL, NLS, TPS, and JCK provided critical clinical or bioinformatic insights for the study. AMT, CLG, and GPC co-wrote the manuscript with critical feedback and input from all authors. **Corresponding Authors**

- 722 Correspondence to Glen Carter or Benjamin Howden.
- 723 Data Availability

- 724 The data presented in the study are deposited under Bioprojects PRJNA565795,
- 725 PRJNA433676, PRJNA856406, and PRJNA856406.

References

727

- 1. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a
- 729 systematic analysis. *The Lancet* **399**, 629–655 (2022).
- 730 2. Bylicka-Szczepanowska, E. & Korzeniewski, K. Asymptomatic Malaria Infections in the
- 731 Time of COVID-19 Pandemic: Experience from the Central African Republic. *Int. J. Environ.*
- 732 *Res. Public. Health* **19**, 3544 (2022).
- 733 3. Global HIV & AIDS statistics Fact sheet. https://www.unaids.org/en/resources/fact-
- 734 sheet.
- 4. GBD 2019 Collaborators. Global mortality from dementia: Application of a new method
- and results from the Global Burden of Disease Study 2019. Alzheimers Dement. N. Y. N 7,
- 737 e12200 (2021).
- 5. Arias, C. A. & Murray, B. E. The rise of the *Enterococcus*: beyond vancomycin resistance.
- 739 *Nat. Rev. Microbiol.* **10**, 266–278 (2012).
- 740 6. Top, J., Willems, R. & Bonten, M. Emergence of CC17 Enterococcus faecium: from
- 741 commensal to hospital-adapted pathogen. FEMS Immunol. Med. Microbiol. 52, 297–308
- 742 (2008).
- 743 7. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in
- 744 enterococci. *Antimicrob. Agents Chemother.* **37**, 1563–1571 (1993).
- 8. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO
- priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–
- 747 327 (2018).
- 9. Montero, C. I., Stock, F. & Murray, P. R. Mechanisms of Resistance to Daptomycin in
- 749 Enterococcus faecium. Antimicrob. Agents Chemother. (2008) doi:10.1128/AAC.00774-07.

- 750 10. Greene, M. H. et al. Risk Factors and Outcomes Associated With Acquisition of
- 751 Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant *Enterococcus. Open*
- 752 *Forum Infect. Dis.* **5**, ofy185 (2018).
- 753 11. Egli, A. et al. Association of daptomycin use with resistance development in
- 754 Enterococcus faecium bacteraemia—a 7-year individual and population-based analysis.
- 755 *Clin. Microbiol. Infect.* **23**, 118.e1-118.e7 (2017).
- 756 12. Diaz, L. et al. Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse
- 757 Daptomycin MICs. *Antimicrob. Agents Chemother.* (2014).
- 758 13. Lellek, H. et al. Emergence of daptomycin non-susceptibility in colonizing
- vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. Int. J.
- 760 *Med. Microbiol.* **305**, 902–909 (2015).
- 761 14. Kelesidis, T., Tewhey, R. & Humphries, R. M. Evolution of high-level daptomycin
- resistance in *Enterococcus faecium* during daptomycin therapy is associated with limited
- 763 mutations in the bacterial genome. J. Antimicrob. Chemother. 68, 1926–1928 (2013).
- 764 15. Werth, B. J. et al. Defining Daptomycin Resistance Prevention Exposures in
- 765 Vancomycin-Resistant Enterococcus faecium and E. faecalis. Antimicrob. Agents
- 766 *Chemother.* **58**, 5253–5261 (2014).
- 767 16. Turner, A. M., Lee, J. Y. H., Gorrie, C. L., Howden, B. P. & Carter, G. P. Genomic
- 768 Insights Into Last-Line Antimicrobial Resistance in Multidrug-Resistant Staphylococcus and
- 769 Vancomycin-Resistant Enterococcus. Front. Microbiol. 12, (2021).
- 770 17. Li, L. et al. Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-
- 771 Resistant Enterococcus faecium in Australasia and Is Associated With Heterogeneous and
- 772 Novel Mutations. *Front. Microbiol.* **12**, 749935 (2021).

- 773 18. Bass, N. M. et al. Rifaximin Treatment in Hepatic Encephalopathy. N. Engl. J. Med.
- 774 **362**, 1071–1081 (2010).
- 775 19. Shayto, R. H., Abou Mrad, R. & Sharara, A. I. Use of rifaximin in gastrointestinal and
- 776 liver diseases. *World J. Gastroenterol.* **22**, 6638–6651 (2016).
- 777 20. Sherry, N. L. et al. Pilot study of a combined genomic and epidemiologic surveillance
- 778 program for hospital-acquired multidrug-resistant pathogens across multiple hospital
- networks in Australia. *Infect. Control Hosp. Epidemiol.* **42**, 573–581 (2021).
- 780 21. Gorrie, C. L. et al. Key parameters for genomics-based real-time detection and
- 781 tracking of multidrug-resistant bacteria: a systematic analysis. Lancet Microbe 2, e575–
- 782 e583 (2021).
- 783 22. Miller, W. R., Bayer, A. S. & Arias, C. A. Mechanism of Action and Resistance to
- 784 Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb. Perspect. Med.
- 785 **6**, a026997 (2016).
- 786 23. Prater, A. G. et al. Environment Shapes the Accessible Daptomycin Resistance
- 787 Mechanisms in *Enterococcus faecium*. *Antimicrob*. *Agents Chemother*. **63**, e00790-19.
- 788 24. Bæk, K. T. et al. Stepwise Decrease in Daptomycin Susceptibility in Clinical
- 789 Staphylococcus aureus Isolates Associated with an Initial Mutation in rpoB and a
- 790 Compensatory Inactivation of the clpX Gene. Antimicrob. Agents Chemother. (2015).
- 791 25. Cui, L. et al. An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and
- 792 Vancomycin in *Staphylococcus aureus*. *Antimicrob*. *Agents Chemother*. (2010)
- 793 doi:10.1128/AAC.00437-10.
- 794 26. Goldstein, B. P. Resistance to rifampicin: a review. J. Antibiot. (Tokyo) 67, 625–630
- 795 (2014).

- 796 27. Rios, R. et al. Genomic Epidemiology of Vancomycin-Resistant Enterococcus faecium
- 797 (VREfm) in Latin America: Revisiting The Global VRE Population Structure. Sci. Rep. 10,
- 798 5636 (2020).
- 799 28. Duchêne, S. et al. Genome-scale rates of evolutionary change in bacteria. *Microb*.
- 800 *Genomics* **2**, e000094 (2016).
- 801 29. Lebreton, F. et al. Emergence of Epidemic Multidrug-Resistant Enterococcus faecium
- from Animal and Commensal Strains. *mBio* **4**, e00534-13.
- 803 30. Raven, K. E. et al. A decade of genomic history for healthcare-associated
- 804 Enterococcus faecium in the United Kingdom and Ireland. Genome Res. 26, 1388–1396
- 805 (2016).
- 806 31. Goel, A., Rahim, U., Nguyen, L. H., Stave, C. & Nguyen, M. H. Systematic review with
- meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. *Aliment*.
- 808 *Pharmacol. Ther.* **46**, 1029–1036 (2017).
- 809 32. Lee, R. A. et al. Daptomycin-Resistant Enterococcus Bacteremia Is Associated With
- 810 Prior Daptomycin Use and Increased Mortality After Liver Transplantation. *Open Forum*
- 811 Infect. Dis. 9, ofab659 (2022).
- 812 33. Morley, V. J. et al. An adjunctive therapy administered with an antibiotic prevents
- enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen. *eLife* **9**,
- 814 e58147 (2020).
- 815 34. Bender, J. K. et al. Update on prevalence and mechanisms of resistance to linezolid,
- tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.
- 817 Drug Resist. Updat. **40**, 25–39 (2018).


- 818 35. Tran, T. T. et al. Whole-Genome Analysis of a Daptomycin-Susceptible Enterococcus
- faecium Strain and Its Daptomycin-Resistant Variant Arising during Therapy. Antimicrob.
- 820 Agents Chemother. **57**, 261–268 (2013).
- 821 36. Zaw, M. T., Emran, N. A. & Lin, Z. Mutations inside rifampicin-resistance determining
- region of *rpoB* gene associated with rifampicin-resistance in *Mycobacterium tuberculosis*.
- 823 *J. Infect. Public Health* **11**, 605–610 (2018).
- 824 37. Lee, J. Y. H. et al. Global spread of three multidrug-resistant lineages of
- Staphylococcus epidermidis. Nat. Microbiol. **3**, 1175–1185 (2018).
- 826 38. Guérillot, R. et al. Convergent Evolution Driven by Rifampin Exacerbates the Global
- Burden of Drug-Resistant *Staphylococcus aureus*. *mSphere* **3**, e00550-17.
- 828 39. Albarillo, F. S., Medina, R. E., Joyce, C. S., Darji, H. & Santarossa, M. Daptomycin-
- resistant VRE infections: a descriptive analysis at a single academic centre. *Infect. Dis.* **53**,
- 830 393–395 (2021).
- 40. Teillant, A., Gandra, S., Barter, D., Morgan, D. J. & Laxminarayan, R. Potential burden
- of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the
- USA: a literature review and modelling study. *Lancet Infect. Dis.* **15**, 1429–1437 (2015).
- 834 41. Berríos-Torres, S. I. et al. Activity of Commonly Used Antimicrobial Prophylaxis
- 835 Regimens against Pathogens Causing Coronary Artery Bypass Graft and Arthroplasty
- 836 Surgical Site Infections in the United States, 2006–2009. *Infect. Control Hosp. Epidemiol.*
- **35**, 231–239 (2014).
- 838 42. Dyar, O. J., Huttner, B., Schouten, J. & Pulcini, C. What is antimicrobial stewardship?
- 839 *Clin. Microbiol. Infect.* **23**, 793–798 (2017).

- 840 43. Lee, R. S. et al. The changing landscape of vancomycin-resistant Enterococcus
- faecium in Australia: a population-level genomic study. J. Antimicrob. Chemother. 73,
- 842 3268-3278 (2018).
- 843 44. Snyder, E. E. et al. PATRIC: The VBI PathoSystems Resource Integration Center.
- 844 *Nucleic Acids Res.* **35**, D401–D406 (2007).
- 845 45. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2.
- 846 *Genome Biol.* **20**, 257 (2019).
- 46. Humphries, R. M. The New, New Daptomycin Breakpoint for *Enterococcus* spp. *J.*
- 848 *Clin. Microbiol.* **57**, e00600-19.
- 849 47. Lam, M. M. et al. Comparative analysis of the complete genome of an epidemic
- hospital sequence type 203 clone of vancomycin-resistant Enterococcus faecium. BMC
- 851 *Genomics* **14**, 595 (2013).
- 852 48. Bankevich, A. et al. SPAdes: A New Genome Assembly Algorithm and Its Applications
- 853 to Single-Cell Sequencing. *J. Comput. Biol.* **19**, 455–477 (2012).
- 854 49. Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* **27**, 592–593
- 855 (2011).
- 856 50. Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and
- evolutionary analyses in R. *Bioinformatics* **35**, 526–528 (2019).
- 858 51. Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T.-Y. ggtree: an r package for
- visualization and annotation of phylogenetic trees with their covariates and other
- associated data. *Methods Ecol. Evol.* **8**, 28–36 (2017).
- 861 52. Crispell, J., Balaz, D. & Gordon, S. V. HomoplasyFinder: a simple tool to identify
- homoplasies on a phylogeny. *Microb. Genomics* **5**, e000245 (2019).

- 863 53. Lees, J. A., Galardini, M., Bentley, S. D., Weiser, J. N. & Corander, J. pyseer: a
- comprehensive tool for microbial pangenome-wide association studies. *Bioinformatics*
- **34**, 4310–4312 (2018).
- 866 54. de Been, M. et al. Core Genome Multilocus Sequence Typing Scheme for High-
- Resolution Typing of *Enterococcus faecium*. *J. Clin. Microbiol.* **53**, 3788–3797 (2015).
- 868 55. Croucher, N. J. et al. Rapid phylogenetic analysis of large samples of recombinant
- bacterial whole genome sequences using Gubbins. *Nucleic Acids Res.* **43**, e15 (2015).
- 870 56. Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: A Fast and
- 871 Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol. Biol.*
- 872 *Evol.* **32**, 268–274 (2015).
- 873 57. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal
- structure of heterochronous sequences using TempEst (formerly Path-O-Gen). Virus Evol.
- 875 **2**, vew007 (2016).
- 876 58. Suchard, M. A. et al. Bayesian phylogenetic and phylodynamic data integration using
- 877 BEAST 1.10. Virus Evol. 4, vey016 (2018).
- 878 59. Minin, V. N. & Suchard, M. A. Counting labeled transitions in continuous-time
- 879 Markov models of evolution. *J. Math. Biol.* **56**, 391–412 (2008).
- 880 60. Minin, V. N. & Suchard, M. A. Fast, accurate and simulation-free stochastic mapping.
- 881 Philos. Trans. R. Soc. B Biol. Sci. **363**, 3985–3995 (2008).
- 882 61. Monk, I. R., Tree, J. J., Howden, B. P., Stinear, T. P. & Foster, T. J. Complete Bypass of
- Restriction Systems for Major *Staphylococcus aureus* Lineages. *mBio* **6**, e00308-15.
- 884 62. Zhang, Y., Werling, U. & Edelmann, W. Seamless Ligation Cloning Extract (SLiCE)
- Cloning Method. in DNA Cloning and Assembly Methods (eds. Valla, S. & Lale, R.) 235–244
- 886 (Humana Press, 2014). doi:10.1007/978-1-62703-764-8 16.

887 Pidot, S. J. et al. Increasing tolerance of hospital Enterococcus faecium to handwash 63. alcohols. Sci. Transl. Med. 10, eaar6115 (2018). 888 64. 889 Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals 890 and human. J. Basic Clin. Pharm. 7, 27-31 (2016). 891 65. Heine, H. S., Bassett, J., Miller, L., Purcell, B. K. & Byrne, W. R. Efficacy of Daptomycin 892 against Bacillus anthracis in a Murine Model of Anthrax Spore Inhalation. Antimicrob. 893 Agents Chemother. 54, 4471–4473 (2010). 894

895



898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

Figure 1. A. Manhattan plot of 10,530 variants, displayed by position on the reference genome and significance association with daptomycin resistance (univariate analysis using a linear mixed model). The dashed line shows the Bonferroni-corrected significance threshold. **B.** Percentage of daptomycin-resistant strains for each mutation within RpoB. The mutations within the rifampicin resistance determining region (RRDR) are shown in bold. Mutations coloured in red were associated with daptomycin resistance. The total number of strains containing each mutation is shown above each bar. C. Maximum-likelihood core-SNP-based phylogeny of clinical VREfm (n=1000) inferred from 6,574 SNPs, demonstrating the presence of RpoB mutations in daptomycin-resistant isolates. Overlaid are the results of in silico multilocus sequence type (MLST), daptomycin phenotypic testing, and mutations associated with daptomycin resistance in RpoB. In the first circle, ST is not shown for uncommon STs (n≤5). The scale bar indicates number of nucleotide substitutions per site (top), with an approximation of SNP distance (in parentheses). D. Rifampicin susceptibility testing results for the WT, isogenic rpoB and liaRS isogenic mutants and complement strains (designated with -C) (n=3). E. Daptomycin susceptibility testing results for the WT, rpoB and liaRS isogenic mutants and complement strains (designated with -C) (n=3). The median MIC for each strain is shown.





Figure 2. A. Map of 4,476 VREfm genomes included in this study. Circle size corresponds to total number of genomes (binned into categories), and colour corresponds to region of isolation. Country coordinates used are the country centroid position. Map was generated in R using ggplot2. **B.** The frequency of various RpoB mutations within the rifampicin resistance determining region (RRDR) in 4,476 VREfm genomes, sampled from 43 MLSTs. Bars are coloured by the number of isolates from each region of isolation containing the mutation. The identified daptomycin resistance associated mutations are coloured in red.



924

925

926

927

928

929

930

931

932

933

934

935


936

937

938

939

Figure 3. A. Maximum-likelihood, core-SNP-based phylogeny for 4,476 VREfm inferred from 9,277 core-genome SNPs, demonstrating the presence of the S491F RpoB mutation in international VREfm. Overlaid is the region of isolation for each strain and the presence of the S491F mutation. The coloured branches indicate the three VREfm clusters identified with cgMLST used as input for Bayesian evolutionary analyses. The scale bar indicates number of nucleotide substitutions per site (top), with an approximation of SNP distance (in parentheses). B. Bayesian phylodynamic analyses showing the maximum-clade credibility (MCC) trees of the three VREfm clusters with the timing of emergence for each lineage. Cluster 1 (n=219) was inferred from a core alignment of 1,869,554 bp containing 329 SNP sites; Cluster 2 (n=85) was inferred from an alignment of 1,524,024 bp containing 541 SNP sites; and Cluster 3 (n=68) was inferred from an alignment of 1,860,780 bp containing 764 SNP sites. The time in years is given on the x axis. The presence of the S491F RpoB trait for each isolate is shown in purple. Overlaid onto the MCC trees is the first instance of FDA approval for rifaximin (2004) and for hepatic encephalopathy (HE) (2010). C. Violin plots for the most recent common ancestor (MCRA) for each cluster, representing when the RpoB S491F mutation first emerged, with 95% HPD intervals. Overlaid onto violin plots is the FDA approval date for rifaximin (2004).



942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

Figure 4. A. Timeline of the mouse experiment. VREfm-colonised mice (n=5 for vehicle, n=10 for rifampicin, n=10 for rifaximin, n=10 for daptomycin) received a human-equivalent dose of vehicle, rifampicin, or rifaximin (twice per day for rifaximin) for 7 days by oral gavage or subcutaneous injection with daptomycin for 7 days. CRO=ceftriaxone; DAP=daptomycin; RIFAX=rifaximin; RIF=rifampicin. Figure to scale. B. Percentage of total mice with rifampicinresistant VREfm strains C. or daptomycin-resistant VREfm strains after 7 days of antibiotic treatment. **D.** Percentage of VREfm from each mouse (n=50 colonies per mouse) that were resistant to rifampicin E. or daptomycin after 7 days of antibiotic treatment. Points represent an individual mouse. Percentage was calculated from rifampicin or daptomycin MIC values (either resistant or susceptible) from 50 VREfm colonies isolated from each mouse. Boxes represent the median and interquartile range for each group. F. Overview of the RpoB mutations identified in the rifampicin-resistant colonies. Each point represents a single colony. Isolates are separated by each RpoB mutation and grouped into either daptomycinsusceptible or daptomycin-resistant. The RpoB mutations coloured in red had an association with daptomycin resistance. n values represent the number of isolates containing each mutation for rifaximin and rifampicin, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, ****P<0.0001; unpaired t-test (vehicle versus rifampicin or vehicle versus rifaximin and rifampicin verses daptomycin or rifaximin verses daptomycin).




Figure 5. A. Maximum-likelihood core-SNP-based phylogeny of clinical VREfm (n=100) inferred from 12,430 SNPs. Overlaid is the results of *in silico* MLST, rifaximin treatment group, rifampicin phenotypic testing, daptomycin phenotypic testing, and mutations in RpoB. Mutations associated with daptomycin resistance are bolded. The scale bar indicates number of nucleotide substitutions per site (top), with an approximation of SNP distance (in parentheses). **B.** Rifampicin susceptibility data for clinical VREfm (n=50 per group). Red bars represent percent of rifampicin-resistant isolates. A Fisher's exact test comparing the percentage of rifampicin resistance in the control versus rifaximin, P < 0.0001. **C.** Daptomycin susceptibility data for clinical VREfm (n=50 per group). Red bars represent percent of daptomycin-resistant isolates. A Fisher's exact test comparing the percentage of daptomycin resistance in the control versus rifaximin, P < 0.0001.